<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Allergy, Asthma and Immunology">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>04</Month>
        <Day>27</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Grading Histopathology Features of Graft-versus-host Disease in Animal Models; A Systematic Review</title>
    <FirstPage>235</FirstPage>
    <LastPage>244</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Hami</FirstName>
        <LastName>Ashraf</LastName>
        <affiliation locale="en_US">Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Farid</FirstName>
        <LastName>Kosari</LastName>
        <affiliation locale="en_US">Department of Pathology and Laboratory Medicine, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>08</Month>
        <Day>29</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>02</Month>
        <Day>05</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Graft-versus-host disease (GvHD), a frequent and severe complication following allogeneic hematopoietic stem cell transplantation, presents substantial morbidity and mortality risks. The crucial role of histopathological examination in diagnosing and grading GvHD, particularly within animal models, is pivotal for elucidating disease mechanisms and assessing emerging therapies. This systematic review aims to critically evaluate the various grading systems for GvHD in animal models, emphasizing histopathological characteristics. In this endeavor, we meticulously examined original research articles sourced from PubMed, Scopus, Web of Science, and Google Scholar. Our findings reveal a diverse array of grading systems, each differing in the tissues examined, criteria evaluated, severity scoring scales, and the granularity of the information provided. Predominantly, skin, liver, and gut tissues are assessed, though some systems also incorporate lung and thymus evaluations. This review will delve into the alignment between clinical and histological grading in animal models of GvHD, also casting light on prospective advancements and the impact of technological progress. In conclusion, our analysis underscores the imperative need for uniform criteria and consistent application of grading systems. Such standardization is essential to foster comparability across studies and enhance the translation of preclinical discoveries into clinical applications.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/3907</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/3907/2070</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>27</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">The Efficacy of Omalizumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Severe Allergic Asthma</title>
    <FirstPage>245</FirstPage>
    <LastPage>256</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Emel</FirstName>
        <LastName>Atayik</LastName>
        <affiliation locale="en_US">Department of Allergy and Clinical Immunology, Konya City Hospital, University of Health Sciences, Konya, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>Gokhan</FirstName>
        <LastName>Aytekin</LastName>
        <affiliation locale="en_US">Department of Allergy and Clinical Immunology, Konya City Hospital, University of Health Sciences, Konya, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>&#x130;sa</FirstName>
        <LastName>Aydin</LastName>
        <affiliation locale="en_US">Department of ENT, University of Health Sciences, Konya City Hospital, Konya, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>Etem</FirstName>
        <LastName>Omeroglu</LastName>
        <affiliation locale="en_US">Department of Pathology, Konya City Hospital, University of Health Sciences, Konya, Turkey</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>01</Month>
        <Day>22</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>29</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Chronic rhinosinusitis whit nasal polyps (CRSwNP) is the most common comorbid disease accompanying asthma. Omalizumab is a recombinant anti-immunoglobulin (Ig) E antibody, and studies suggest that omalizumab may also affect CRSwNP regardless of asthma. We aimed to assess the effect of omalizumab treatment on CRSwNP accompanying severe allergic asthma (SAA) patients.
Clinical data including spirometry measurements, serum/nasal secretion biomarker levels were collected. NP scores and CRS scores (Lund-Mancay [LM] scores) were also recorded before omalizumab treatment, as well as at the 4th and 12th months of omalizumab treatment.
Twenty-one patients with both CRSwNP and SAA who underwent omalizumab therapy were assessed. There was a significant difference among forced expiratory volume (FEV1), ACT scores, NP scores, LM scores, serum IgE, and blood eosinophil levels of the patients before omalizumab therapy at the 4th and 12th months of omalizumab treatment. A significant negative correlation was observed between &#x2206;FEV1 and &#x2206;NP scores (r=&#x2212;0.485), between &#x2206;ACT and &#x2206;NP scores (r=&#x2212;0.469), and &#x2206;ACT and &#x2206;LM scores (r=&#x2212;0.436). When we grouped the patients who benefited from 1 year of omalizumab therapy and those who did not in terms of NP, there was no difference between the two groups related to local eosinophil and local IgE levels in the nasal polyp biopsy.
Omalizumab treatment is effective for asthma and CRSwNP in patients with CRSwNP accompanied by SAA. Improvement in asthma is associated with improvement in CRSwNP. The efficacy of omalizumab on NP in patients with CRSwNP accompanied by SAA is independent of local IgE and eosinophil counts.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/3752</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/3752/2071</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>27</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">High-expression of V-domain Imuunoglobulin Suppressor of T-cell Activation (VISTA) Is Correlated with Advanced Pathological Features in Patients with Pancreatic Ductal Adenocarcinoma</title>
    <FirstPage>257</FirstPage>
    <LastPage>271</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Hamid</FirstName>
        <LastName>Nickho</LastName>
        <affiliation locale="en_US">Immunology Research Center, Institute of Immunology and Infectious Disease, Iran University  of Medical Sciences, Tehran, Iran AND Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Reza</FirstName>
        <LastName>Falak</LastName>
        <affiliation locale="en_US">Immunology Research Center, Institute of Immunology and Infectious Disease, Iran University of Medical Sciences, Tehran, Iran AND Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Fereshteh</FirstName>
        <LastName>Rezagholizadeh</LastName>
        <affiliation locale="en_US">Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran AND Cellular and Molecular Research Centre, Iran University of Medical Sciences, Tehran, Iran AND Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Majid</FirstName>
        <LastName>Khoshmirsafa</LastName>
        <affiliation locale="en_US">Immunology Research Center, Institute of Immunology and Infectious Disease, Iran University  of Medical Sciences, Tehran, Iran AND Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammad Taghi</FirstName>
        <LastName>Joghataei</LastName>
        <affiliation locale="en_US">Cellular and Molecular Research Centre, Iran University of Medical Sciences, Tehran, Iran AND Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University  of Medical Sciences, Tehran, Iran AND Department of Innovation in Medical Education (DIME), Faculty of Medicine, University of Ottawa, Ottawa, Canada</affiliation>
      </Author>
      <Author>
        <FirstName>Shabnam</FirstName>
        <LastName>Mollazadeh Ghomi</LastName>
        <affiliation locale="en_US">Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran AND Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Elaheh</FirstName>
        <LastName>Safari</LastName>
        <affiliation locale="en_US">Immunology Research Center, Institute of Immunology and Infectious Disease, Iran University  of Medical Sciences, Tehran, Iran AND Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>10</Month>
        <Day>23</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>02</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">V-domain Imuunoglobulin suppressor of T-cell activation (VISTA) seems a promising immune checkpoint target in cancer treatment; however, its prognostic significance in pancreatic ductal adenocarcinoma (PDAC) remains unknown.
Herein, 29 fresh PDAC tissue samples were used to evaluate the mRNA expression level of VISTA by real-time polymerase chain reaction (PCR). Besides, 40 formalin-fixed paraffin-embedded PDAC tissues were collected to evaluate VISTA protein expression by immunohistochemistry.
Real-time PCR indicated that high expression of VISTA was significantly correlated with advanced stages of the cancer, based on the tumor/node/metastasis (TNM) stagingand tumor cell differentiation.&#xA0; Immunohistochemistry results also showed significant correlation of the elevated cytoplasmic expression of VISTA with advanced TNM stages, older age of the patients and was a worsening indicator, regarding the disease-specific survival.
In conclusion, we found that the expression levels of VISTA can be a potential prognostic biomarker in PDAC patients and its elevated levels are correlated with poor prognostic outcomes.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/3935</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/3935/2072</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>27</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Polyomavirus BK-Specific CD4+ T Cells Response to VP1 Stimulation  in Kidney Transplant Recipients</title>
    <FirstPage>272</FirstPage>
    <LastPage>287</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Nasrin</FirstName>
        <LastName>Noshadi</LastName>
        <affiliation locale="en_US">Department of Biology, Marvdasht Branch, Islamic Azad University, Marvdasht, Iran AND Department of Biology, Fars Science and Research Branch, Islamic Azad University, Marvdasht, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Ramin</FirstName>
        <LastName>Yaghoubi</LastName>
        <affiliation locale="en_US">Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Afsoon</FirstName>
        <LastName>afshari</LastName>
        <affiliation locale="en_US">Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Mohsen</FirstName>
        <LastName>Forouzanfar</LastName>
        <affiliation locale="en_US">Department of Biology, Marvdasht Branch, Islamic Azad University, Marvdasht, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Saeede</FirstName>
        <LastName>Soleimanian</LastName>
        <affiliation locale="en_US">Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>03</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>03</Month>
        <Day>28</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Reactivation of Polyomavirus BK (BKPyV) is related to reduction of T cells response in kidney transplant recipients (KTRs). Here, we examined the differentiation of CD4+ T cells subsets in response to BKPyV KTRs, using the BKPyV VP1 (viral capsid protein 1) as a stimulator.
We categorized our samples into three distinct groups: 1. Reactive BKPyV (BKPyV+), 2. non-reactive (BKPyV-) KTRs and 3. Healthy controls. BKPyV- KTRs and healthy controls stimulated with VP1 and BKPyV+ unstimulated with VP1. The human CD4+ T cells was stimulation with VP1-Ag. The proportion of CD4+ T lymphocytes and their various subsets, including naive T cells, central memory T cells (TCM), and effector memory T cells (TEM) was measured using flowcytometry.
BKPyV- KTRs VP1+ indicated significantly lower TCM CD4+ T cells in contrast with both BKPyV+ KTRs VP1-, and healthy controls VP1+. This indicates that VP1 stimulation may reduce TCM cell levels in these patients. The percentage of TEM in the BKPyV- KTRs VP1+ group was significantly less prevalent than the BKPyV+ KTRs VP1- group. The percentage of TEM cells in BKPyV+ KTRs VP1- was significantly lower than the healthy controls VP1+. Stimulation with VP1 protein significantly increased the frequency of cytotoxic CD4+ T cells in BKPyV- KTRs VP1+ compared to BKPyV+ KTRs VP1-.
The present research has shown that the VP1 stimulation of CD4+ T cells can induce cytotoxic CD4+ T cells responses that may help overcome BKPyV infection in KTRs. However, VP1 stimulation may also differentially affect TCM and TEM CD4+ T cells subsets.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/3984</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/3984/2073</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>27</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">The Effect of Exosomes Isolated from Poly (I:C) Treated Human Wharton's Jelly Mesenchymal Stem Cells on CD4+CD25+Foxp3+ Regulatory T Cells</title>
    <FirstPage>288</FirstPage>
    <LastPage>298</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Ava</FirstName>
        <LastName>Misaghian</LastName>
        <affiliation locale="en_US">Department of Immunology, School of Medicine Ahvaz Jundishapur University of Medical sciences, Ahvaz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Ata A</FirstName>
        <LastName>Ghadiri</LastName>
        <affiliation locale="en_US">Department of Immunology, School of Medicine Ahvaz Jundishapur University of Medical sciences, Ahvaz, Iran AND Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University  of Medical Sciences, Ahvaz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Ali</FirstName>
        <LastName>Asadirad</LastName>
        <affiliation locale="en_US">Department of Immunology, School of Medicine Ahvaz Jundishapur University of Medical sciences, Ahvaz, Iran AND Cancer Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Sareh</FirstName>
        <LastName>Amirzadeh</LastName>
        <affiliation locale="en_US">Department of Infertility, Infertility Research and Treatment Center of ACECR, Ahvaz, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Afshin</FirstName>
        <LastName>Amari</LastName>
        <affiliation locale="en_US">Department of Immunology, School of Medicine Ahvaz Jundishapur University of Medical sciences, Ahvaz, Iran AND Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University  of Medical Sciences, Ahvaz, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>11</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>04</Month>
        <Day>17</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Mesenchymal stem cells (MSCs) are a potential cell therapy candidate for autoimmune and inflammatory diseases due to their multilineage capacity and immune modulating function. MSCs exert immunomodulatory effects on target cells through the secretion of exosomes. Inflammatory conditions such as Toll-like receptors (TLRs) engagement can change the biological functions and immunomodulatory activities of MSCs and the contents of exosomes derived from MSCs are changed. Regulatory T-cells (Treg) are crucial for maintaining immune cell homeostasis and self-tolerance. Our study aimed to investigate the impact of isolated exosomes from hWJ-MSCs that were treated with Poly (I:C) on regulatory CD4 CD25 Foxp3 T-cells.
MSCs were harvested from human umbilical cord Wharton&#x2019;s Jelly by explant method. Stem cells were treated by Polyinosinic-polycytidylic acid sodium salt (Poly (I:C)) for 48 hours. Exosomes were extracted from supernatant of cells and Scanning electron microscopy (SEM) and Dynamic light scattering (DLS) were performed for them. Peripheral blood mononuclear cells (PBMCs) isolated from the healthy donors were stimulated with PHA (Phytohemagglutinin) and co-cultured with Poly (I:C) treated hWJ-MSCs derived exosome and untreated hWJ-MSCs derived exosome or without hWJ-MSCs-derived exosome for 6 days. Then, frequency of CD4+CD25+ Foxp3+ regulatory T cells was measured by flow cytometry.
Our results showed that exosomes isolated from Poly (I:C) treated hWJ-MSCs significantly increased frequency of CD4+CD25+ Foxp3+ regulatory T cells compared to the untreated hWJ-MSCs derived exosome group and control group.
Stimulation by TLR3 improved the anti-inflammatory features of exosomes that were derived from hWJ-MSCs by increasing the frequency of Treg cells.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/3996</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/3996/2074</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>27</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Invariant Natural Killer T Cells Regulate Conventional Dendritic Cell Maturation to Re-establish Immune Tolerance to Rheumatoid Arthritis  in DBA/1 Mice</title>
    <FirstPage>299</FirstPage>
    <LastPage>310</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Yaqi</FirstName>
        <LastName>Wang</LastName>
        <affiliation locale="en_US">Medical School of Hebei University, Baoding, China AND Key Laboratory of Pathogenesis Mechanism and Control of Inflammatory-autoimmune Diseases, Baoding, China</affiliation>
      </Author>
      <Author>
        <FirstName>Min</FirstName>
        <LastName>Zhang</LastName>
        <affiliation locale="en_US">Medical School of Hebei University, Baoding, China AND Key Laboratory of Pathogenesis Mechanism and Control of Inflammatory-autoimmune Diseases, Baoding, China</affiliation>
      </Author>
      <Author>
        <FirstName>Shengde</FirstName>
        <LastName>Chen</LastName>
        <affiliation locale="en_US">Medical School of Hebei University, Baoding, China AND Key Laboratory of Pathogenesis Mechanism and Control of Inflammatory-autoimmune Diseases, Baoding, China</affiliation>
      </Author>
      <Author>
        <FirstName>Zheng</FirstName>
        <LastName>Li</LastName>
        <affiliation locale="en_US">Affiliated Hospital of Hebei University, Baoding, China</affiliation>
      </Author>
      <Author>
        <FirstName>Ming</FirstName>
        <LastName>Meng</LastName>
        <affiliation locale="en_US">Medical School of Hebei University, Baoding, China AND Key Laboratory of Pathogenesis Mechanism and Control of Inflammatory-autoimmune Diseases, Baoding, China</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>11</Month>
        <Day>27</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>02</Month>
        <Day>16</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Rheumatoid arthritis (RA) is a type of autoimmune disease that results in immune disorder and excessive inflammatory response due to a reduction of self-tolerance. Invariant natural killer T (iNKT) cells can effectively alleviate clinical symptoms and hyper-inflammation in RA, but their mechanism of action is not well-defined. This study aims to investigate the mechanism of iNKT cell therapy for RA.
We established a DBA/1 mouse model for RA and treated it with specific iNKT cells. A cytometric bead array was used to measure the amounts of cytokines in the serum. Flow cytometry was then employed to identify different subsets of helper T cells (Th), the frequency of conventional dendritic cells (cDC), the expression of CD80, CD86, programmed cell death ligand 1 (PD-L1), and PD-L2 on cDC surfaces, and associated pathway proteins.
iNKT cell treatment reduced Th1/Th2 and Th17/ regulatory T (Treg) cell ratios while increasing interleukin-4 (IL-4) and IL-10. It enhanced the generation of immature cDCs, and it upregulated the level of PD-L2 by stimulating the signal transducer and activator of transcription 3 (STAT3) signaling pathway. Meanwhile, it activated the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway and inhibited the nuclear factor kappa B (NF-&#x3BA;B) pathway.
According to our findings, iNKT cell treatment increased the expression of phosphates STAT3 &#xA0;in lymph node cDC, causing them to upregulate PD-L2 molecules. While activating the ERK1/2 pathway and inhibiting the NF-&#x3BA;B pathway, tolerogenic cDC was produced, restoring immune homeostasis and correcting excessive inflammation. These results deliver new insights into the treatment of RA by iNKT cells.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/3960</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/3960/2076</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>27</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Moderate-intensity Exercise Alleviates Rat&#x2019;s Systemic Inflammation Induced by Repeated Exposure to Lipopolysaccharide</title>
    <FirstPage>311</FirstPage>
    <LastPage>320</LastPage>
    <AuthorList>
      <Author>
        <FirstName>HamidReza</FirstName>
        <LastName>Rezaei Moghaddam</LastName>
        <affiliation locale="en_US">Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Toktam</FirstName>
        <LastName>Sahranavard</LastName>
        <affiliation locale="en_US">Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Ramin</FirstName>
        <LastName>Rezaee</LastName>
        <affiliation locale="en_US">Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammad Hossein</FirstName>
        <LastName>Boskabady</LastName>
        <affiliation locale="en_US">Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran AND Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Zahra</FirstName>
        <LastName>Gholamnezhad</LastName>
        <affiliation locale="en_US">Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran AND Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>02</Month>
        <Day>22</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>02</Month>
        <Day>13</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">The protective impacts of physical activity against inflammatory and oxidative stress conditions have been demonstrated. In this study, the impacts of moderate-intensity exercise on oxidative stress-associated factors and proinflammatory cytokines levels as well as the count of white blood cells (WBC) were assessed in a lipopolysaccharide (LPS)-triggered model of inflammation.
Wistar rats were randomized into these groups (8 rats in each): (1) control; (2) LPS; (3) moderate exercise (EX); and (4) moderate exercise + LPS (EX+LPS). Exercise groups were trained for 8 weeks (30 min, 6 days/week) at 15 m/min speed. During the final week of the experiment, 1 mg/kg/day of intraperitoneal LPS was administered for 5 days. On day 56, from the rats&#x2019; hearts, peripheral blood was taken for biochemical evaluation.
LPS enhanced serum levels of C-reactive protein (CRP), interleukin (IL)- 1&#x3B2;, tumor necrosis factor-&#x3B1; (TNF-&#x3B1;), metabolites of nitric oxide, and malondialdehyde (MDA), as well as the counts of total WBC, monocytes, neutrophils, and eosinophils, but decreased serum levels of thiol as well as superoxide dismutase (SOD) and catalase (CAT) activity versus the control rats. Moderate exercise reduced the levels of thiol, CAT, and SOD, but increased TNF-&#x3B1; level, and total WBC, neutrophils, eosinophils, and monocytes counts versus the control group. In the EX+LPS group, moderate exercise decreased cell counts and diminished MDA, TNF-&#x3B1;, IL-1&#x3B2;, and CRP levels, while increasing thiol level, CAT, and SOD versus the LPS group.
In our study, exercise preconditioning reduced inflammation induced by LPS by ameliorating inflammatory cytokine levels, WBC counts, and oxidative damage, while improving antioxidant defenses.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/3778</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/3778/2077</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>27</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Assessment of the Anti-cancer Effects of Camel Milk Exosomes (CMEXOs) on Murine Colorectal Cancer Cell Line (CT-26)</title>
    <FirstPage>321</FirstPage>
    <LastPage>329</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Samira</FirstName>
        <LastName>Karbasi</LastName>
        <affiliation locale="en_US">Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Nafiseh</FirstName>
        <LastName>Erfanian</LastName>
        <affiliation locale="en_US">Student Research Committee, Department of Molecular Medicine, Faculty of Medicine, Birjand University  of Medical Sciences, Birjand, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Hamideh</FirstName>
        <LastName>Dehghan</LastName>
        <affiliation locale="en_US">Student Research Committee, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Asghar</FirstName>
        <LastName>Zarban</LastName>
        <affiliation locale="en_US">Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran AND Department of Clinical Biochemistry, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>mahammad hasan</FirstName>
        <LastName>Namaei</LastName>
        <affiliation locale="en_US">Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammad Yahya</FirstName>
        <LastName>Hanafi-Bojd</LastName>
        <affiliation locale="en_US">Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Saeed</FirstName>
        <LastName>nasseri</LastName>
        <affiliation locale="en_US">Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>07</Month>
        <Day>16</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>22</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Today, camel milk consumption in the Middle East is trendy because it is believed that it reduces the risk of cancer. Recently, studies have discovered that most of milk's beneficial effects are because of its nanoparticles, especially exosomes. The objective of the present research was to investigate the anti-cancer effects of camel milk exosomes (CMEXOs) in the murine colorectal cancer cell line (CT-26).
Our findings verified the existence of exosomes measuring approximately 114.1&#xB1;3.4 nm in diameter. Through MTT and migration assays, we established that CMEXOs exhibit dose-dependent anti-proliferative and anti-migration effects on the CT-26 cell line. Furthermore, our study showed that treatment with CMEXOs led to a reduction in TNF-&#x3B1; and IL-6 gene expression in CT-26 cells.
While additional in vivo studies are required, our data demonstrate that CMEXOs have anti-proliferative and anti-migration effects on CT-26, possibly by influencing crucial genes within the inflammation pathway.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/3874</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/3874/2078</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>27</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Nebulized Dexmedetomidine Alleviates Oxidative Stress in Ventilator-induced Lung Injury via Keap1-Nrf2-ARE Pathway</title>
    <FirstPage>330</FirstPage>
    <LastPage>338</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Jun</FirstName>
        <LastName>Zha</LastName>
        <affiliation locale="en_US">Department of Anesthesiology, The Second Affiliated Hospital, Soochow University, Suzhou, China AND Department of Anesthesiology, The Second Affiliated Hospital, Wannan Medical College, Wuhu, China</affiliation>
      </Author>
      <Author>
        <FirstName>Youjia</FirstName>
        <LastName>Yu</LastName>
        <affiliation locale="en_US">Department of Anesthesiology, Suzhou Xiangcheng People&#x2019;s Hospital, Suzhou, China</affiliation>
      </Author>
      <Author>
        <FirstName>Ji</FirstName>
        <LastName>Zhu</LastName>
        <affiliation locale="en_US">Department of Anesthesiology, The Second Affiliated Hospital, Wannan Medical College, Wuhu, China</affiliation>
      </Author>
      <Author>
        <FirstName>Guiru</FirstName>
        <LastName>Li</LastName>
        <affiliation locale="en_US">Department of Anesthesiology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University,  Suzhou, China</affiliation>
      </Author>
      <Author>
        <FirstName>Xiaolin</FirstName>
        <LastName>Deng</LastName>
        <affiliation locale="en_US">Department of Anesthesiology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University,  Suzhou, China</affiliation>
      </Author>
      <Author>
        <FirstName>Hong</FirstName>
        <LastName>Xie</LastName>
        <affiliation locale="en_US">Department of Anesthesiology, The Second Affiliated Hospital, Soochow University, Suzhou, China</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>29</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>03</Month>
        <Day>11</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">This study aimed to explore the underlying mechanism of nebulized dexmedetomidine (DEX) in ameliorating ventilator-induced lung injury (VILI)-induced oxidative stress in rats.
Forty 7 to 8-week-old Sprague-Dawley rats at the specific pathogen-free level were randomized into the control group, model group, nebulized dexmedetomidine (WH-YM) group, and dexmedetomidine intravenous infusion (JM-YM) group, each containing 10 rats. Except for the control group, rats in the other groups underwent mechanical ventilation (tidal volume, &#xA0;40 mL/kg; respiratory rate, 70 breaths per minute; inspiratory-to-expiratory ratio, 1:2; fraction of inspired oxygen, 21%; positive end-expiratory pressure, 0 cmH2O). Nebulized DEX (6.3 &#xB5;g/kg), and isodose intravenous DEX &#xA0;were given to rats of WH-YM and JM-YM groups prior to ventilation. Post 4-hour ventilation, rats were euthanized. Lung tissue wet-to-dry weight ratio, H&amp;amp;E staining for assessing diffuse alveolar damage (DAD), and expression levels of Nrf2 and Keap1 detected by qRT-PCR and Western blot were compared. Inflammatory markers TNF-&#x3B1;, IL-2, and IL-6, and oxidative stress indices malondialdehyde (MDA) and superoxide dismutase (SOD), were quantified in lung tissues and serum samples using commercial kits.&#xA0;
Rats in the WH-YM and JM-YM groups demonstrated significant ameliorations in the wet-to-dry weight ratio and DAD score, decreased Keap1, TNF-&#x3B1;, IL-2, and IL-6 levels in lung tissues and serum samples, but increased Nrf2 and SOD level than those of controls. These changes were more pronounced in the WH-YM group than in the JM-YM group.
DEX effectively alleviates VILI-induced oxidative stress and inflammation via the Keap1-Nrf2-ARE signaling pathway., especially in the nebulized administration.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/4018</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/4018/2079</pdf_url>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>05</Month>
        <Day>27</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome  and Myocarditis: A Case Report and Literature Review on Fatal Complications  of Reactivated Viral Infections</title>
    <FirstPage>339</FirstPage>
    <LastPage>346</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Amin</FirstName>
        <LastName>Tajerian</LastName>
        <affiliation locale="en_US">Department of Pediatrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Ali</FirstName>
        <LastName>Pourvali</LastName>
        <affiliation locale="en_US">Department of Pediatrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Masoud</FirstName>
        <LastName>Movahedi</LastName>
        <affiliation locale="en_US">Division of Allergy and Clinical Immunology, Department of Pediatrics, Tehran University  of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Maryam</FirstName>
        <LastName>Mohammadi</LastName>
        <affiliation locale="en_US">Department of Pediatrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Behzad</FirstName>
        <LastName>Khansarinejad</LastName>
        <affiliation locale="en_US">3 Department of Microbiology and Immunology, Arak University of Medical Sciences, Arak, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Matin</FirstName>
        <LastName>Pourmatin</LastName>
        <affiliation locale="en_US">National Forensic Medicine Organization, Arak, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Yazdan</FirstName>
        <LastName>Ghandi</LastName>
        <affiliation locale="en_US">Department of Pediatrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Mohammad Ali</FirstName>
        <LastName>Daneshmand</LastName>
        <affiliation locale="en_US">Daneshmand Pathology Laboratory, Arak, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>10</Month>
        <Day>29</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>02</Month>
        <Day>12</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a complex and potentially fatal hypersensitivity condition. We present a unique case report and literature review focusing on DRESS syndrome-associated myocarditis resulting from reactivated viral infections in a 21-year-old female.
3 weeks after 5-day oral co-trimoxazole consumption due to acne, she developed symptoms consistent with DRESS syndrome, including a generalized maculopapular rash. Despite prednisolone treatment, the patient developed fatal fulminant myocarditis linked to HHV-6 and CMV reactivation.
The patient's death highlights the importance of early recognition and careful management of DRESS syndrome, especially considering the potential viral reactivation that can lead to severe complications. Postmortem investigations revealed that viral reactivation caused myocarditis. Careful consideration must be given to corticosteroid usage in DRESS treatment, as inappropriate prescribing may promote viral reactivation and subsequent complications.
While high-dose corticosteroids initiated within the first week effectively suppress HHV-6 reactivation. Conversely, low-dose or late-start high-dose corticosteroids prove ineffective in preventing HHV-6 viremia. Late- onset or low- dose corticosteroids may lead to fatal complications following the primary viral reactivation.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/3940</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/3940/2042</pdf_url>
  </Article>
</Articles>
